undamentalytics Newsletter
Sign in

Prestige Consumer Healthcare Inc. (PBH) stock

Add to watchlist

Add holding +

NYSE: PBH NYSE Pharmaceuticals Next results ~November 5, 2026

B Fundamentals grade

Prestige Consumer Healthcare Inc. is a US-listed company in the pharmaceuticals industry. Its financial year ends in March.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

~$51

Cash-flow model

Base case. Range ~$29–$82 across our lower- and higher-growth cases (-3%–7% a year).

Price vs value

Modestly undervalued

The price is inside our value range, 3% below our base value.

Price used: $49.73, November 2, 2026

Prestige Consumer Healthcare Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 2 selling0 purchases and 8 sales by directors and officers, last 12 monthsInsider trades
  • Funds145 adding, 195 cuttingOf 49 active managers that changed their stake, 24 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Prestige Consumer Healthcare files

Where Prestige Consumer Healthcare stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $1.10bn, down 1.4% on a year earlier, a smaller fall than the 4.3% decline a quarter earlier. That puts it 16 of 18 for growth among the pharmaceuticals companies we cover. Free-cash-flow margin fell to 21.3% from 23.9% a year earlier. Operating margin narrowed to 26.3% from 30.0%. The diluted share count is down 3.6% on a year earlier, which lifts each remaining share. Against its peers on growth, profitability, cash generation and balance sheet, it grades B. It passes 1 of our 6 financial-health checks. Our cash-flow model value is $41.23 a share, against a share price of $48.01. At that price, our model says the market is pricing in about 3.4% a year of cash-flow growth for five years, faster than the 0.3% a year revenue growth it has delivered.

Source: 10-Q filed August 6, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 5, 2026 (estimated)

Prestige Consumer Healthcare Inc.'s trailing-twelve-month revenue fell 1.4% year on year, with a free-cash-flow margin of 21.3%. Where it stands out: operating margin of 26.3% ranks 7 of 67 pharmaceuticals companies we cover.

Our discounted-cash-flow model values the business at ~$51 per share in the base case (~$29–$82 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Long-term debt rising: Long-term debt rose 102% year over year, to 44% of total assets.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • High operating margin. 26.3% of revenue is left as operating profit, against a median of -5.9% for pharmaceuticals companies we cover.
  • Strong cash generation. 21.3% of revenue turned into free cash flow, against a median of 10.1% for pharmaceuticals companies we cover.
  • Shrinking share count. Diluted shares fell 3.6% in a year, so each share owns more of the business.

Things to watch

  • Results due soon. Results are expected around 5 November; the share price can move sharply on the day.
  • Revenue shrinking. Revenue fell 1.4% over the last 12 months.
  • Margins narrowing. Operating margin is down 3.8 points on a year ago.
  • High debt. Long-term debt exceeds cash by $1.9bn, more than 1.5 times annual revenue.
  • Gross margin slipping. Gross margin is down 2.6 points on a year ago.
  • Below peers: long-term debt as % of assets. Long-term debt as % of assets of 43.9% ranks 41 of 53 pharmaceuticals companies we cover (median 23.8%).

Latest results: FY2027 Q1

Filed August 6, 2026
Earnings per share
$0.98 against an average estimate of $0.88: beat by 12.0%
Revenue
$266m, up 6.5% on a year earlier
Share reaction
+3.5% in the first session after the results on August 6, 2026, against +0.5% for the S&P 500
Next report
November 5, 2026; average EPS estimate $1.07

Prestige Consumer Healthcare's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+1.4%
  • 1 week+3.3%
  • 1 month+9.9%
  • This year-19.4%
  • 1 year-17.9%
  • 5 years-19.0%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$1.1B
Operating margin
26.3%
Net margin
15.6%
EPS (TTM, diluted)
$3.57

Growth

Revenue growth
−1.4%
Change in growth rate
+2.9 pts
Share count change
−3.6%

Cash

Free cash flow (TTM)
$235M
FCF margin
21.3%
Stock pay % of revenue
1.0%

Earnings

Last results
August 6, 2026
Next results (est.)
November 5, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Leadership
  2. Results
  3. Agreement
  4. Agreement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Prestige Consumer Healthcare Inc. valuation models and calculator

What the price is pricing in

The share price implies about 3.5% a year of cash-flow growth for five years.That is close to the 0.3% a year revenue growth Prestige Consumer Healthcare has delivered.

  • Priced in3.5%
  • Last 12 months-1.4%
  • 3 years a year-0.7%
  • 5 years a year0.3%

Our cash-flow model with every input fixed except growth over the next five years, solved for the growth at which the model value equals the share price ($48.78, Nov 3, 2026). Cash-flow growth then fades to 2.5% a year; discount rate 8.5%. Delivered figures are revenue growth from SEC filings. This is a model exercise, not investment advice or a forecast of the share price. All companies

Fundamentalytics rating

model v1.6 · 2026-11-03
Hold12-month view
12-month price target
~$51
Price used
$48.78close November 3, 2026
Implied change
▲ +5%
Uncertainty
High

How we got here: a discounted-cash-flow model of Prestige Consumer Healthcare Inc.'s free cash flow after stock-based pay with after-tax interest added back ($236M, FY2027 Q1 TTM), growing 12.1% and 3.3% in the next two years (forecasts, guidance and its record), then back to 2% by year five, and fading to 2.5%, discounted at 8.5%. Lower and higher growth cases span ~$28–~$82 ; that spread sets a 35% margin before we rate Buy or Sell.

Produced by Fundamentalytics' automated valuation model on November 3, 2026, using delayed market prices. Rating meanings, methodology and conflicts: recommendations disclosure and research disclaimer. General research, not personal advice — it does not consider your circumstances. Prices can fall as well as rise.

Our value per share comes from a discounted-cash-flow model of Prestige Consumer Healthcare Inc.'s free cash flow after stock-based pay ( $236M, FY2027 Q1 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.

Valuation models

We value Prestige Consumer Healthcare Inc. as an operating company, with every model that fits that kind of business. Cost of equity 8.1%: the 10-year Treasury yield (4.9%) plus a beta of 0.7 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. ~$51 ~$29–$82 Primary model, counts double
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$45 ~$47–$94 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. ~$42 ~$27–$69 Included
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. ~$43 ~$36–$53 Included
Combined value Weighted average of the models that apply: the primary model (cash-flow model (dcf)) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$47 ~$42–$51 4 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Prestige Consumer Healthcare Inc. with Pharmaceuticals in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

What moves the value

  • Revenue growth 5 points lower ▼ −50%
  • Revenue growth 5 points higher ▲ +66%
  • Free-cash-flow margin 1 point lower ▼ −9%
  • Last year's free-cash-flow margin change, if it persists ▼ −20%
  • Discount rate 1 point higher ▼ −29%
Value per share under different assumptions
Discount rate ↓ / growth → −5% growth0% growth5% growth10% growth15% growth20% growth
7% $31$56$90$135$193$268
8.5% $14$32$57$89$130$184
10% $4$18$37$61$93$133

Valuation multiples over time Market data may be delayed

At fiscal year end 20162017201820192020202120222023202420252026Now
Share price$53.39$55.56$33.72$29.91$36.68$44.08$52.94$62.63$72.56$85.97$59.27$49.73
Market value$2.8bn$3.0bn$1.8bn$1.6bn$1.9bn$2.2bn$2.7bn$3.1bn$3.6bn$4.3bn$2.9bn$2.4bn
+ Net debt (− = net cash)$1.6bn$2.2bn$2.0bn$1.8bn$1.7bn$1.5bn$1.5bn$1.3bn$1.1bn$902m$936m$2.0bn
Enterprise value$4.5bn$5.1bn$3.8bn$3.3bn$3.5bn$3.7bn$4.2bn$4.4bn$4.7bn$5.2bn$3.8bn$4.4bn
Multiples
Price / sales 3.5x3.4x1.7x1.6x1.9x2.4x2.5x2.8x3.2x3.8x2.7x2.2x
Price / earnings 28.4x42.7x5.3x—13.2x13.5x13.1x—17.4x20.1x15.2x13.9x
Price / free cash flow 16.4x20.3x9.1x8.7x9.3x10.5x10.8x14.1x15.2x17.7x11.7x10.2x
EV / EBITDA 15.7x22.2x15.2x33.7x11.0x11.3x11.5xn/m12.7x14.2x11.2x13.5x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

67 /100

Moderate moat

How hard Prestige Consumer Healthcare's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 5 / 20

    Net income has been a median 4.7% of total assets over 10 years.

  • Pricing power 19 / 20

    Gross margin has been a median 56.2%, moving by 1.4 percentage points (standard deviation) across 10 years.

  • Durability 10 / 20

    Operating margin has been a median 29.4%; its worst year was -2.1%.

  • Cash conversion 20 / 20

    Free cash flow was positive in 10 of 10 years, at a median 21.3% of revenue.

  • Discipline 18 / 20

    The diluted share count fell 4.8% over five years; stock-based pay has been a median 1.0% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (72 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 5, 2026, before the open. Analysts expect revenue of $329m and EPS of $1.07 (range $1.05 to $1.08) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $4.57 +4% $1.3bn +17%
Next $5.08 +11% $1.4bn +6%

Next year's EPS estimate has moved +1.4% in 90 days, across 8 analysts.

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 $0.88 $0.98 +12.0%
Mar 2026 $1.39 $1.23 −11.5%
Dec 2025 $1.16 $1.14 −1.4%
Sept 2025 $0.97 $0.86 −11.3%

Adjusted EPS as companies report it, against the average analyst estimate.

How our valuation uses these forecasts

Our cash-flow model grows Prestige Consumer Healthcare Inc.'s revenue by +12.1% next year and +3.3% the year after, then fades back toward its own record by year five. Next year's rate weighs analysts' consensus (+17.1%, weight 67%) and the company's own record (+2.0%, weight 33%) . How the weights are set.

Analyst recommendations

7 analysts, Oct 2026
Buy571%
Hold229%
Sell00%

Monthly trend

  1. Oct 20261427
  2. Sep 20261427
  3. Aug 20261427

Counts of recommendations published by analysts covering Prestige Consumer Healthcare Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
11.8%
of tradable shares
Days to cover
7.69
at average volume
Short interest, 1 month
+1%
to September 30, 2026
Held by institutions
—
of shares
Held by insiders
1.4%
of shares
Employees
890
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −17.9%

$60.60 on October 31, 2025 to $49.73

ThenNowEffect
Revenue (last 12 months) $1.1bn $1.1bn −1.4%
Net margin 19.0% 15.6% −18.1%
P/E multiple 14.2x 13.9x −2.1%
Share count 50m 48m +3.8%

Biggest factor: net margin.

Last 3 years −16.5%

$59.56 on November 3, 2023 to $49.73

ThenNowEffect
Revenue (last 12 months) $1.1bn $1.1bn −2.2%
P/S multiple 2.6x 2.2x −17.3%
Share count 50m 48m +3.3%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
PBH+74%+3%−2%+28%−21%−19%
Industry peers (median)−20%−52%−14%−2%+9%−12%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
PBH75%67%50%67%33%55%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
PBH−13%−21%−17%−17%−36%−36%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 3, 2015: 54% from March 1, 2017 to March 11, 2019. Getting back needed a 116% gain, reached on August 6, 2021, 879 days after the low.

Price behaviour

52-week range
$44.77 – $70.21
From 52-week high
−29.2%
vs 50-day average
+2.5%
vs 200-day average
−7.9%
Volatility (1 year)
33%
Beta vs S&P 500
-0.07

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
7 up, 5 down
typical move ±5.7%
After a week
6 up, 6 down
typical move ±6.0%
After a month
7 up, 5 down
typical move ±6.9%
Results releasedNext dayS&P 500 next day5 days21 days
August 6, 2026 +3.5% +0.5% −3.1% −1.4%
May 13, 2026 −8.9% +1.4% −6.4% −5.1%
February 5, 2026 −1.0% +0.6% −0.1% −1.2%
November 6, 2025 +0.2% −1.0% +0.3% +0.8%
August 7, 2025 −12.7% +0.7% −14.1% −12.5%
May 8, 2025 +7.2% +0.6% +7.0% +5.2%
February 6, 2025 +14.3% −0.6% +12.6% +14.1%
November 7, 2024 +3.5% +1.2% +6.6% +7.3%
August 8, 2024 −2.4% +2.8% +1.2% +7.0%
May 14, 2024 −5.7% +1.7% −7.7% −8.0%
February 8, 2024 +9.2% +0.6% +9.3% +18.6%
November 2, 2023 +0.1% +2.8% −3.0% +1.7%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Options strategies

All options ideas

How Prestige Consumer Healthcare Inc.’s listed options are priced, and three ways to use them that follow from our valuation. Quotes are delayed, read November 2, 2026. Check the live chain at your broker before trading.

Cash-secured put

Not offered: fundamentals grade B (needs B+ or better).

We suggest selling a put only on well-rated companies, at a strike where the price you would pay if assigned (strike less premium) is at or below our fair value.

Covered call

Not offered: no liquid call at or above our price target — the model says the upside is worth more than any listed strike.

For holders: sell a call at a strike at or above our fair value, so the shares are only sold at a price the model calls full value.

Collar

Not offered: the shares trade below our fair value: a collar caps upside the model expects.

For holders of a stock trading at or above our fair value: buy a put for a floor and sell a call to pay for it.

General research, not personal advice. Options can lose you more than you expect and are not suitable for everyone: put sellers can be made to buy shares that keep falling, call sellers give up gains above the strike, and results or news can move prices sharply. Chances shown are approximations from each option’s delta. Spreads, fees and early assignment are not modelled.

Prestige Consumer Healthcare Inc. in five measures

Fundamentals grade B
Growth Profitability Cash Balance sheet Value

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Prestige Consumer Healthcare Inc.
$1.1B $1.1B $1.1B $1.1B FY24 Q2 FY25 Q1 FY25 Q4 FY27 Q1 Revenue (TTM), FY24 Q2: $1.1B Revenue (TTM), FY24 Q3: $1.1B Revenue (TTM), FY24 Q4: $1.1B Revenue (TTM), FY25 Q1: $1.1B Revenue (TTM), FY25 Q2: $1.1B Revenue (TTM), FY25 Q3: $1.1B Revenue (TTM), FY25 Q4: $1.1B Revenue (TTM), FY26 Q1: $1.1B Revenue (TTM), FY26 Q2: $1.1B Revenue (TTM), FY26 Q3: $1.1B Revenue (TTM), FY26 Q4: $1.1B Revenue (TTM), FY27 Q1: $1.1B $1.1B

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Revenue (TTM)
FY24 Q2 $1.1B
FY24 Q3 $1.1B
FY24 Q4 $1.1B
FY25 Q1 $1.1B
FY25 Q2 $1.1B
FY25 Q3 $1.1B
FY25 Q4 $1.1B
FY26 Q1 $1.1B
FY26 Q2 $1.1B
FY26 Q3 $1.1B
FY26 Q4 $1.1B
FY27 Q1 $1.1B
Revenue growth, TTM YoY Prestige Consumer Healthcare Inc.
-6% -4% -2% 0% 2% 4% FY24 Q2 FY25 Q1 FY25 Q4 FY27 Q1 Revenue growth, TTM YoY, FY24 Q2: 1.7% Revenue growth, TTM YoY, FY24 Q3: 2.3% Revenue growth, TTM YoY, FY24 Q4: -0.2% Revenue growth, TTM YoY, FY25 Q1: -1.5% Revenue growth, TTM YoY, FY25 Q2: -1.5% Revenue growth, TTM YoY, FY25 Q3: -1.4% Revenue growth, TTM YoY, FY25 Q4: 1.1% Revenue growth, TTM YoY, FY26 Q1: 0.6% Revenue growth, TTM YoY, FY26 Q2: -0.0% Revenue growth, TTM YoY, FY26 Q3: -1.3% Revenue growth, TTM YoY, FY26 Q4: -4.3% Revenue growth, TTM YoY, FY27 Q1: -1.4% -1.4%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Revenue growth, TTM YoY
FY24 Q2 1.7%
FY24 Q3 2.3%
FY24 Q4 -0.2%
FY25 Q1 -1.5%
FY25 Q2 -1.5%
FY25 Q3 -1.4%
FY25 Q4 1.1%
FY26 Q1 0.6%
FY26 Q2 -0.0%
FY26 Q3 -1.3%
FY26 Q4 -4.3%
FY27 Q1 -1.4%
Operating margin (TTM) Prestige Consumer Healthcare Inc.
-10% 0% 10% 20% 30% 40% FY24 Q2 FY25 Q1 FY25 Q4 FY27 Q1 Operating margin (TTM), FY24 Q2: -1.8% Operating margin (TTM), FY24 Q3: -1.8% Operating margin (TTM), FY24 Q4: 30.4% Operating margin (TTM), FY25 Q1: 29.6% Operating margin (TTM), FY25 Q2: 29.3% Operating margin (TTM), FY25 Q3: 29.6% Operating margin (TTM), FY25 Q4: 29.6% Operating margin (TTM), FY26 Q1: 30.0% Operating margin (TTM), FY26 Q2: 29.9% Operating margin (TTM), FY26 Q3: 29.2% Operating margin (TTM), FY26 Q4: 28.4% Operating margin (TTM), FY27 Q1: 26.3% 26.3%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Operating margin (TTM)
FY24 Q2 -1.8%
FY24 Q3 -1.8%
FY24 Q4 30.4%
FY25 Q1 29.6%
FY25 Q2 29.3%
FY25 Q3 29.6%
FY25 Q4 29.6%
FY26 Q1 30.0%
FY26 Q2 29.9%
FY26 Q3 29.2%
FY26 Q4 28.4%
FY27 Q1 26.3%
FCF margin (TTM) Prestige Consumer Healthcare Inc.
18% 20% 22% 24% 26% FY24 Q2 FY25 Q1 FY25 Q4 FY27 Q1 FCF margin (TTM), FY24 Q2: 19.1% FCF margin (TTM), FY24 Q3: 20.5% FCF margin (TTM), FY24 Q4: 21.3% FCF margin (TTM), FY25 Q1: 22.1% FCF margin (TTM), FY25 Q2: 22.9% FCF margin (TTM), FY25 Q3: 22.2% FCF margin (TTM), FY25 Q4: 21.4% FCF margin (TTM), FY26 Q1: 23.9% FCF margin (TTM), FY26 Q2: 23.0% FCF margin (TTM), FY26 Q3: 24.2% FCF margin (TTM), FY26 Q4: 22.6% FCF margin (TTM), FY27 Q1: 21.3% 21.3%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period FCF margin (TTM)
FY24 Q2 19.1%
FY24 Q3 20.5%
FY24 Q4 21.3%
FY25 Q1 22.1%
FY25 Q2 22.9%
FY25 Q3 22.2%
FY25 Q4 21.4%
FY26 Q1 23.9%
FY26 Q2 23.0%
FY26 Q3 24.2%
FY26 Q4 22.6%
FY27 Q1 21.3%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Where the money goes

FY2026, from the 10-K

Each dollar Prestige Consumer Healthcare took in during FY2026, followed through to profit: what it cost to make, what went on running the business, and what was left after tax.

  1. Revenue $1.1B
  2. Cost of revenue $493M · 45.3%
  3. Gross profit $596M · 54.7%
  4. Selling, general and admin $116M · 10.7%
  5. Other operating costs $170M · 15.6%
  6. Operating income $309M · 28.4%
  7. Income tax $67.2M · 6.2%
  8. Interest and other $51.9M · 4.8%
  9. Net income $190M · 17.5%

Shares of revenue. Source: Prestige Consumer Healthcare's 10-K for FY2026, as filed with the SEC. "Other" lines are what the reported lines leave unexplained.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2010 Mar 2010 2011 Mar 2011 2012 Mar 2012 2013 Mar 2013 2014 Mar 2014 2015 Mar 2015 2016 Mar 2016 2017 Mar 2017 2018 Mar 2018 2019 Mar 2019 2020 Mar 2020 2021 Mar 2021 2022 Mar 2022 2023 Mar 2023 2024 Mar 2024 2025 Mar 2025 2026 Mar 2026 LTM Jun 2026
Income
Revenue 293 337 441 617 596 713 806 882 1,041 976 963 943 1,087 1,128 1,125 1,138 1,089 1,105
Gross profit 153 171 227 344 336 406 467 500 577 556 552 547 621 625 624 634 596 591
EBITDA 90 86 114 205 202 225 284 231 249 99 320 328 362 10 373 367 341 323
Operating income 78 76 103 192 189 208 260 206 215 68 291 297 330 −22 342 337 309 290
Net income 32 29 37 66 73 78 100 69 340 −36 142 165 205 −82 209 215 190 172
Diluted EPS $0.64 $0.58 $0.73 $1.27 $1.39 $1.49 $1.88 $1.30 $6.34 −$0.69 $2.78 $3.25 $4.04 −$1.65 $4.17 $4.29 $3.91 $3.57
Growth (year on year)
Revenue — +15.0% +31.1% +39.9% −3.4% +19.8% +13.0% +9.4% +18.0% −6.3% −1.3% −2.0% +15.2% +3.8% −0.2% +1.1% −4.3% −1.4%
EBITDA — −3.9% +31.7% +80.6% −1.5% +11.5% +26.1% −18.5% +7.5% −60.1% +222.5% +2.3% +10.5% −97.2% — −1.6% −7.2% −11.9%
Operating income — −2.8% +35.0% +86.6% −1.7% +10.0% +25.4% −21.0% +4.8% −68.7% +331.3% +2.1% +10.9% −106.8% — −1.7% −8.1% −13.8%
Net income — −9.0% +27.4% +76.0% +10.9% +7.8% +27.7% −30.5% +389.3% −110.5% — +15.7% +24.7% −140.1% — +2.5% −11.3% −19.2%
Diluted EPS — −9.4% +25.9% +74.0% +9.4% +7.2% +26.2% −30.9% +387.7% −110.9% — +16.9% +24.3% −140.8% — +2.9% −8.9% −16.2%
Margins
Gross margin 52.4% 50.8% 51.6% 55.7% 56.3% 56.9% 57.9% 56.7% 55.4% 56.9% 57.3% 58.0% 57.1% 55.4% 55.5% 55.8% 54.7% 53.5%
EBITDA margin 30.7% 25.6% 25.7% 33.2% 33.9% 31.6% 35.2% 26.2% 23.9% 10.2% 33.2% 34.7% 33.3% 0.9% 33.2% 32.3% 31.3% 29.2%
Operating margin 26.8% 22.6% 23.3% 31.1% 31.7% 29.1% 32.3% 23.3% 20.7% 6.9% 30.2% 31.5% 30.4% −2.0% 30.4% 29.6% 28.4% 26.3%
Net margin 11.0% 8.7% 8.4% 10.6% 12.2% 11.0% 12.4% 7.9% 32.6% −3.7% 14.8% 17.5% 18.9% −7.3% 18.6% 18.9% 17.5% 15.6%
Free-cash-flow margin 20.1% 25.6% 15.2% 20.6% 18.3% 21.0% 21.4% 16.5% 19.0% 18.3% 21.0% 22.6% 23.0% 19.7% 21.3% 21.4% 22.6% 21.3%
Cash flow
Cash from operations 59 87 67 138 112 156 176 149 210 189 217 236 260 230 249 252 258 249
Capital spending 1 1 1 10 3 6 4 3 13 10 15 22 10 8 10 8 11 14
Free cash flow 59 86 67 127 109 150 173 146 198 179 203 213 250 222 239 243 246 235
Stock-based pay 2 4 3 4 5 7 10 8 9 7 8 9 9 12 14 11 11 11
Free cash flow after stock pay 57 82 64 124 104 143 163 138 189 171 195 205 241 210 225 232 236 224
Balance sheet
Cash 41 13 19 16 28 21 27 42 33 28 95 32 27 58 46 98 64 89
Total debt 0 487 1,135 978 938 1,594 1,653 2,222 2,013 1,813 1,745 1,495 1,495 1,360 1,135 1,000 1,000 2,045
Net debt (negative = net cash) −41 474 1,116 962 909 1,572 1,625 2,180 1,980 1,785 1,650 1,463 1,468 1,302 1,089 902 936 1,956
Diluted shares 50m 50m 51m 51m 52m 53m 53m 53m 54m 52m 51m 51m 51m 50m 50m 50m 49m 48m
Returned to shareholders
Dividends — — — 0 0 0 0 — — — — — — — — — — —
Buybacks — — — — — — — 0 0 50 57 12 0 50 25 52 156 122
Total returned — — — 0 0 0 0 0 0 50 57 12 0 50 25 52 156 122

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

1 of 6 checks passed · June 30, 2026
What it owns · $4.6bn
Short-term assets $497mLonger-term assets $4.1bn
What it owes, and who funded it · $4.6bn
Short-term liabilities $154mLonger-term liabilities $2.5bnShareholders' equity $1.9bn
  • Short-term assets cover short-term liabilities $497m of assets due within a year against $154m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $497m short-term assets against $2.5bn of longer-dated liabilities.
  • More cash than debt $89m of cash against $2.0bn of debt.
  • Debt below 40% of shareholders' equity Debt is 105% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 102% to 105% over five years.
  • A year's operating cash flow covers at least 20% of debt $249m of operating cash flow against $2.0bn of debt.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Prestige Consumer Healthcare Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2027 Q1 TTM
Buybacks (TTM)
$122M
Returned to shareholders
52%
of free cash flow
Buybacks, last 3 fiscal years
$233M
Diluted share count
−3.6%
year over year
Total shareholder yield
5.1%
dividends 0.0% + buybacks 5.1% of market value
Days sales outstanding
62 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in pharmaceuticals
Last 12 months unless stated PBH TRLV ANIP HRMY INDV AXSM Median
Revenue, last 12 months $1.1bn $1.1bn $978m $960m $1.4bn $865m $276m
Revenue growth, last 12 months −1.4% −3.9% 30.9% 24.3% 16.3% 54.2% 9.9%
Revenue growth, 3-year average −0.7% −0.6% 34.6% 24.4% — 57.0% 5.5%
Revenue growth, latest quarter 6.5% −10.3% 25.9% 30.3% 13.4% 51.9% 6.5%
Gross margin 53.5% 59.5% 60.0% 75.4% 85.0% — 62.0%
Operating margin 26.3% −24.3% 15.4% 24.0% 40.6% −17.5% −5.9%
Operating margin, 3-year average 28.6% −1.4% 8.9% 26.6% — −48.6% −7.4%
Net margin 15.6% −41.6% 11.1% 18.9% 32.8% −18.2% −7.3%
Cash from operations / revenue 22.6% 21.5% 19.4% 37.0% 7.0% −9.5% 10.2%
Free-cash-flow margin 21.3% 17.1% 17.7% 37.0% 2.3% −9.5% 8.6%
Free-cash-flow margin, 3-year average 22.4% 19.0% 17.6% 34.3% — −22.3% 7.4%
Stock pay / revenue 1.0% 1.8% 4.2% 4.3% 2.4% 11.5% 3.6%
Change in share count −3.6% 1.4% 11.6% 0.6% 0.0% 4.7% 1.9%

Median of all 75 companies we cover in pharmaceuticals. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

75 pharmaceuticals companies
Measure Company Peer median Rank
Revenue growth Growth -1.4% 10.0% 55 of 74
Change in growth rate Growth +2.9pp -0.3pp 18 of 74
Gross margin Profitability 53.5% 59.8% 35 of 59
Operating margin Profitability 26.3% -5.9% 7 of 67
Net margin Profitability 15.6% -7.3% 16 of 75
Free-cash-flow margin Cash generation 21.3% 10.1% 16 of 74
Stock pay as % of revenue Cash generation 1.0% 3.6% 10 of 69
Long-term debt as % of assets Balance sheet 43.9% 23.8% 41 of 53
Change in share count Balance sheet -3.6% 1.5% 7 of 62
Days sales outstanding Balance sheet 62 days 72 days 20 of 59

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to March 31, 2026
Segments
Line of business Revenue Share YoY
North American OTC Healthcare $914M 83.9% ▼ 4.8%
International OTC Healthcare $175M 16.1% ▼ 1.5%
Products and services
Line of business Revenue Share YoY
Products $1.1B 99.6% ▼ 4.6%
Gastrointestinal $260M 23.9% ▲ 1.5%
Womens Health $228M 21.0% ▼ 3.8%
Eye and Ear Care $143M 13.2% ▼ 22.0%
Dermatologicals $126M 11.6% ▼ 2.3%
Analgesics $114M 10.5% ▼ 3.2%
Cough and Cold $102M 9.4% ▼ 4.1%
Oral Care $101M 9.3% ▲ 6.3%
Other Otc $15.4M 1.4% ▲ 11.7%
Other $4M 0.4% ▲ 235.4%
Geography
Region Revenue Share YoY
United States $850M 78.1% ▼ 5.3%
Outside the US $238M 21.9% ▼ 0.8%

From Prestige Consumer Healthcare Inc.'s 10-K filed May 14, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$2.5B
Institutions reporting
314
Shares held vs prior quarter
▲ 3.5%
Positions opened / closed
34 / 73

Top buyers and sellers, Q2 2026: 145 institutions bought and 195 sold ; the biggest buyer was Fuller & Thaler Asset Management, Inc (+2.3M shares) and the biggest seller Nomura Asset Management International Inc (−1.1M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $370M 7.8M 14.6% ▲ 6.0%
Ariel Investments, LLC $230M 4.9M 9.1% ▲ 13.9%
Vanguard Portfolio Management LLC $134M 2.8M 5.3% ▲ 0.8%
Dimensional Fund Advisors LP $126M 2.7M 5.0% ▼ 0.4%
Fuller & Thaler Asset Management, Inc. $110M 2.3M 4.3% New
Vanguard Capital Management LLC $101M 2.1M 4.0% ▲ 2.1%
State Street Corp $100M 2.1M 3.9% ▲ 7.4%
Brandes Investment Partners, LP $97M 2.1M 3.8% ▲ 140.1%
Kayne Anderson Rudnick Investment Management LLC $88.5M 1.9M 3.5% ▼ 15.0%
Geode Capital Management, LLC $74.3M 1.6M 2.9% ▲ 7.7%
Allspring Global Investments Holdings, LLC $61.3M 1.3M 2.4% ▼ 18.4%
Morgan Stanley $58.8M 1.2M 2.3% ▼ 8.4%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Prestige Consumer Healthcare Inc.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $424,424 8 trades by 2 insiders · 27% under pre-set plans
Net ▼ $424,424 net selling
Insider Date Trade Shares Price Value
Zerillo Jeffrey Senior VP Operations May 11, 2026 Sell pre-set plan 351 $52.28 $18,350
Zerillo Jeffrey Senior VP Operations May 7, 2026 Sell pre-set plan 305 $54.36 $16,580
Zerillo Jeffrey Senior VP Operations May 5, 2026 Sell pre-set plan 346 $55.32 $19,141
Zerillo Jeffrey Senior VP Operations May 5, 2026 Sell 1,207 $54.99 $66,373
Zerillo Jeffrey Senior VP Operations February 11, 2026 Sell 1,000 $65.93 $65,930
Zerillo Jeffrey Senior VP Operations December 1, 2025 Sell pre-set plan 281 $60.00 $16,860
Zerillo Jeffrey Senior VP Operations November 28, 2025 Sell pre-set plan 719 $60.00 $43,140
Byom John E Director November 25, 2025 Sell 3,000 $59.35 $178,050

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 5, 2026 estimated from the company's past filing pattern, not announced

  • August 6, 2026
  • May 13, 2026
  • February 5, 2026
  • November 6, 2025
  • August 7, 2025
  • May 8, 2025

Recent SEC filings

Data status

When each part of this page on Prestige Consumer Healthcare Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Prestige Consumer Healthcare Inc. in brief

What does Prestige Consumer Healthcare Inc. do?
Prestige Consumer Healthcare Inc. is a US-listed company in the pharmaceuticals industry. Its financial year ends in March.
What is Prestige Consumer Healthcare Inc.'s stock ticker?
Prestige Consumer Healthcare Inc. trades under the ticker PBH on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Prestige Consumer Healthcare Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Prestige Consumer Healthcare Inc. reported revenue of $1.1B, 1.4% lower than a year earlier, according to its SEC filings.
What is Prestige Consumer Healthcare Inc.'s free cash flow?
Prestige Consumer Healthcare Inc.'s free-cash-flow margin is 21.3% of revenue over the trailing twelve months, ranking 16 of the 74 pharmaceuticals companies we cover.
What is Prestige Consumer Healthcare Inc.'s fair value (intrinsic value) per share?
Our discounted-cash-flow model of Prestige Consumer Healthcare Inc.'s free cash flow after stock-based pay gives ~$51 per share in the base case, and ~$29–$82 across growth scenarios. These are model values under stated assumptions — not a price target or a recommendation.
Who are Prestige Consumer Healthcare Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Ariel Investments, LLC and Vanguard Portfolio Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is Prestige Consumer Healthcare Inc. buying back stock, and does it pay a dividend?
Prestige Consumer Healthcare Inc. spent $122M on share repurchases over the trailing twelve months, and its diluted share count fell 3.6% over the year.
What is Prestige Consumer Healthcare Inc.'s market cap?
On November 2, 2026, Prestige Consumer Healthcare Inc.'s market capitalisation was about $2.4B, with a price-to-earnings ratio of 13.9 and net debt of $2B. Market figures come from third-party market data and may be delayed.
How much debt does Prestige Consumer Healthcare Inc. have?
Prestige Consumer Healthcare Inc.'s debt-to-equity ratio is 105.3%, from its latest balance sheet (102.1% five years earlier). The financial health section below sets out its other solvency checks.
Who are Prestige Consumer Healthcare Inc.'s competitors?
In our Pharmaceuticals peer group, the companies closest to Prestige Consumer Healthcare Inc. are Trulieve Cannabis Corp., ANI Pharmaceuticals Inc, Harmony Biosciences Holdings, Inc., Indivior Pharmaceuticals, Inc. and Axsome Therapeutics, Inc. The side-by-side comparison below sets their revenue, margins and growth against Prestige Consumer Healthcare Inc.'s.
Are insiders buying or selling Prestige Consumer Healthcare Inc. stock?
Over the last 12 months, Prestige Consumer Healthcare Inc.'s directors and officers reported 0 open-market purchases and 8 sales on Form 4. The insider trading page charts every trade.
When is Prestige Consumer Healthcare Inc.'s next earnings date?
Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Prestige Consumer Healthcare Inc. announces its own schedule.